Although arterial hypertension is an important factor contributing to cardiovascular complications in coronary patients with and without diabetes mellitus (DM), target values of blood pressure are rarely achieved in practice. The aim of the study was to compare the attainment of target blood pressure in patients with DM who survived myocardial infarction (MI) (group A) with that in patients without DM (group B). A group of 118 patients (both genders, with confirmed diagnosis of MI) was followed for three years, out of which 34 belonged to group A, and 84 to group B. After three years of secondary prevention measures, in group B patients target blood pressure values (TA<140/90mmHg) were registered more often compared to the beginning of the study (84.8% vs 28.6%) (p<0.0001). Group A patients did not have statistically significant higher percentage of target blood pressure values (TA<130/80 mmHg) at the end of the study (11.8% vs 24.2%) (p>0.05), but the percentage of those with TA<140/90mmHg was significantly higher (57.6% vs 18.2%) (p<0.0005). Our analysis of secondary prevention indicated that 21.3% of group A and 12.7% of group B patients did not take β-blockers, but the difference was not statistically significant (p>0.05). In addition, there were no statistically significant differences in the use of ACE inhibitors between group A (84.8%) and group B (89.8%) (p>0.05). Our study of the evaluation of secondary prevention measures in achieving target blood pressure values in patients with and without DM who survived MI demonstrated high prevalence of higher blood pressure values, especially in patients with DM, and still insufficient use of β-blockers and ACE inhibitors. Secondary prevention of cardiovascular events thus has to be intensified, particularly in patients with diabetes.
Chen J, Marciniak TA, Radford MJ, Wang Y, Krumholz HM. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Results from the National Cooperative Cardiovascular Project J Am Coll Cardiol. 1999;34:1388–94.
2.
Mancia G, Backer G, Dominiczak A, Cifkova R, R F, Germano G, et al. European Society of Hyper tension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. J Hypertens. 2007;25:1105–87.
3.
Ho MP, Masoudi FA, Peterson ED, Grunwald GK, Sales AE, Hammermeister KE, et al. Cardiology management improves secondary prevention measures among patients with coronary artery disease. J Am Coll Cardiol. 2004;43:1517–23.
4.
Pyörälä K, Lehto S, Bacquer D, Sutter J, Sans S, Keil U, et al. Risk factor management in diabetic and non-diabetic pati ents with coronary heart disease. Findings from the EUROASPIRE I AND II surveys Diabetologia. 2004;47:1257–65.
5.
Völler H, Reibis R, Pittrow D, Jannowitz C, Wegscheider K, Karmann B, et al. Secondary prevention of diabetic patients with coronary artery disease in cardiac reha bilitation: risk factors, treatment and target level attain ment. Curr Med Res Opin. 2009;25:879–90.
6.
Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previo usly diagnosed diabetes. JAMA. 2004;291:335–42.
7.
Anselmino M, Bartnik M, Malmberg K, Ryden L, Euro Heart Survey Investigators. Manage ment of coronary artery disease in patients with and without diabetes mellitus. Acute management reaso nable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the heart. Eur J Cardiovasc Prev Rehab. 2007;14:28–36.
8.
Sicras-Mainar A, Navarro-Artieda R, Rejas-Gutiérrez J, Fernández-de-Bobadilla J, Frías-Garrido X, Ruiz-Riera R. Use of aspirin for primary and secondary preven tion of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain. BMC Family Practice. 2007;8(60).
9.
Savić T, Janković D, Janković I, Bojanić V, Đinđić B, Miladinović Tasić N, et al. Effects of simvastatin therapy on bone mineral density in hypercholestero lemic postmenopausal woman. Acta Fac Med Naiss. 2010;27(1):13–8.
10.
Brand DA, Newcomer LN, Freiburger A, Tian H. Cardiologists’ practices compared with practice guide lines: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol. 1995;26:1432–6.
11.
Guidelines Committee 2003 European Society of Hypertension - European Society of Cardiology guide lines for the management of arterial hypertension. J Hypertens. 2003;21:1011–53.
12.
Chowdhury TA, Lasker SS, Dyer PH. Comparison of secondary prevention measures after myocardial infarction in subjects with and without diabetes mellitus. J Intern Med. 1999;245(6):565–70.
13.
Akbar DH. Secondary Prevention Measures after Acute Myocardial Infarction: Comparison between Diabetics and Non-Diabetics at a Saudi Teaching Hospital. Med Princ Pract. 2000;9:181–5.
14.
Zuanetti G, Latini R, Maggioni AP, Franzosi M, L S, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation. 1997;96(12):4239–45.
15.
Gustafsson I, Torp-Pedersen C, Køber L, Gustafsson F, Hildebrandt P, Trace Study Group. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. J Am Coll Cardiol. 1999;34(83):9.
16.
R D’ A, AJ B, WB K, JM C. Relation of low diastolic blood pressure to coro nary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ. 1991;303:385–9.
17.
Flack J, Neaton J, Grimm R, Shih J, Cutler J, Ensrud K, et al. for the Multiple Risk Factor Intervention Trial Research Group. Blood pressure and mortality among men with prior myocardial infarction. Circulation. 1995;92:2437–45.
18.
Group UKPDS. Tight blood pressure control and risk of macrovascular and micro vascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–13.
19.
Aleksić E, Stamenković R, Đorđević D, Lazarević G, Vulić D, Tasic I. Prognostic factors in patients who have survived myocardial infarction. Cent Eur J Med. 2010;5:513–9.
20.
Haffner S, Lehto S, Ronnemara T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.
21.
Norhammar A, Malmberg K, Ryden L, Tornvall P, Wallentin L. Under utilisation of evidence-based treat ment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J. 2003;24:838–44.
22.
Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, et al. GRACE Investigators. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events Arch Intern Med. 2004;164:1457–63.
23.
Tenerz A, Lönnberg I, Berne C, Nilsson G, Leppert J. Myocardial infarction and prevalence of diabetes mellitus. Is increased casual blood glucose at admi ssion a reliable criterion for the diagnosis of diabe tes? Eur Heart J. 2001;22:1102–10.
24.
Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, et al. Glucose metabolism in pati ents with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140–4.
25.
Bartnik M, Malmberg K, Hamsten A, Efendic S, A N, Silveira A, et al. Abnormal glucose tolerance - a common risk factor in patients with acute myocardial infarction in comparison with population-based contro ls. J Intern Med. 2004;256(4):288–97.
26.
Assmann G, Schulte H. The Prospective Cardiovascular Münster Study (PROCAM. Am Heart J. 1988;116:1713–24.
27.
Kannel WB, McGee DL. Diabetes and glucose tolera nce as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care. 1979;2:120–6.
28.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk fac tors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control stu dy. Lancet. 2004;364:937–52.
29.
Sicree R, Shaw JE, Zimmet PZ. The Global Burden of Diabetes. Diabetes Atlas. 2006:10 153.
30.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, G D. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients.
31.
Timmer van der H, IC de L, G O, JP H, JC de B, M.J., et al. Zwolle Myocardial Infarction Study Group. Comparison of myocardial perfusion after successful primary percutaneous coro nary intervention in patients with ST-elevation myo cardial infarction with versus without diabetes melli tus. Am J Cardiol. 2005;95:1375–7.
32.
DK MG, H E, CB G, E MO, DJ M, HD W, et al. Influence of diabetes mellitus on clinical outcome across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO-IIb Investigators Eur Heart J. 2000;21:1750–8.
33.
Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, Mc Murray JJ, et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial infarction (VALIANT) trial. Circulation. 2004;110:1572–8.
34.
Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardio vascular disease prevention in clinical practice: execu tive summary. In: Fourth Joint Task Force of the European Society of Cardiology and the Other Societies on Cardiovascular Disease Prevention in Clinical Practice.
35.
Rydén L, Standl E, Bartnik M, Berghe G, Betteridge J, Boer MJ, et al. Guidelines on diabet es, pre-diabetes, and cardiovascular diseases: execu tive summary. The Task Force on Diabetes and Car diovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD. Eur Heart J. 2007;28:88–136.
36.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, JL I, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute. In: National High Blood Pressure Education Pro gram Coordinating Committee Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure Hypertension. 2003. p. 1206–52.
37.
O’Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, et al. on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension reco mmendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003;21:821–48.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
